Objective: To systematically evaluate the clinical efficacy and safety of Yupingfeng combined with pidomomod in the treatment of children with recurrent respiratory infections

so as to provide reference for the clinical treatment. Methods: PubMed

EMBase

CBM

CNKI

VIP and Wanfang database were retrieved to collect the randomized controlled trials (RCTS) of conventional therapy + Yupingfeng in combination with pidomomod (experimental group)

conventional therapy alone

conventional therapy + pidomomod (control group) in the treatment of children with repeated respiratory infections. The retrieval time was from Jan. 2000 to Mar. 2018. After extracting the data and evaluating the quality

Meta-analysis was performed by using RevMan 5.2 software. Results: Totally 12 literature were collected

including 1

175 children. Meta-analysis results showed that the total effective rate of the experimental group was higher than that of the control group (RR=1.25

95%CI from 1.19 to 1.32

P<0.01); the duration of fever

relief time of cough

disappearance time of lung rales and tonsil redness were shorter than those of the control group (P<0.01). After treatment

immunoglobulin levels (IgA

IgM and IgG) and T lymphocyte levels (CD3+

CD4+ and CD4+/CD8+) of the experimental group were higher than those of the control group (P<0.01). No adverse drug reactions were reported in all literature. Conclusion: Yupingfeng combined with pidotimod can significantly improve the immune level of children with recurrent respiratory infections and clinical signs

thereby increasing the total effective rate